91 related articles for article (PubMed ID: 11131676)
1. Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Ueno Y; Hayashi S; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(6A):4081-6. PubMed ID: 11131676
[TBL] [Abstract][Full Text] [Related]
2. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
[TBL] [Abstract][Full Text] [Related]
3. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Fukushima T; Yamamoto M; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 1998; 18(5D):3965-70. PubMed ID: 9854511
[TBL] [Abstract][Full Text] [Related]
5. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII).
Wu PC; Alexander HR; Huang J; Hwu P; Gnant M; Berger AC; Turner E; Wilson O; Libutti SK
Cancer Res; 1999 Jan; 59(1):205-12. PubMed ID: 9892208
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Ikeda K; Soma G; Fukushima T
Anticancer Res; 2002; 22(4):2447-53. PubMed ID: 12174942
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
[TBL] [Abstract][Full Text] [Related]
8. Endothelial-monocyte-activating polypeptide II increases blood-tumor barrier permeability by down-regulating the expression levels of tight junction associated proteins.
Xie H; Xue YX; Liu LB; Liu YH
Brain Res; 2010 Mar; 1319():13-20. PubMed ID: 20083091
[TBL] [Abstract][Full Text] [Related]
9. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs.
Nabors LB; Gillespie GY; Harkins L; King PH
Cancer Res; 2001 Mar; 61(5):2154-61. PubMed ID: 11280780
[TBL] [Abstract][Full Text] [Related]
10. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
Kayton ML; Libutti SK
Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006
[TBL] [Abstract][Full Text] [Related]
11. Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.
Lans TE; Van Horssen R; Eggermont AM; Ten Hagen TL
Anticancer Res; 2004; 24(4):2243-8. PubMed ID: 15330168
[TBL] [Abstract][Full Text] [Related]
12. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
13. Deciphering the immune function and regulation by a TLR of the cytokine EMAPII in the lesioned central nervous system using a leech model.
Schikorski D; Cuvillier-Hot V; Boidin-Wichlacz C; Slomianny C; Salzet M; Tasiemski A
J Immunol; 2009 Dec; 183(11):7119-28. PubMed ID: 19917687
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
15. In situ detection of O6-methylguanine-DNA methyltransferase messenger RNA in paraffin-embedded human astrocytic tumor tissues by nested in situ RT-PCR is useful in predicting chemotherapy-resistance of tumors.
Ohe N; Saio M; Kijima M; Tamakawa N; Suwa T; Kojima Y; Yano H; Kaku Y; Iwama T; Shinoda J; Sakai N; Takami T
Int J Oncol; 2003 Mar; 22(3):543-9. PubMed ID: 12579307
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma.
Oshiro S; Tsugu H; Komatsu F; Ohnishi H; Ueno Y; Sakamoto S; Fukushima T; Soma G
Anticancer Res; 2006; 26(6A):4027-32. PubMed ID: 17195453
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas.
Angileri FF; Aguennouz M; Conti A; La Torre D; Cardali S; Crupi R; Tomasello C; Germanò A; Vita G; Tomasello F
Cancer; 2008 May; 112(10):2258-66. PubMed ID: 18327814
[TBL] [Abstract][Full Text] [Related]
18. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.
Alonso MM; Fueyo J; Shay JW; Aldape KD; Jiang H; Lee OH; Johnson DG; Xu J; Kondo Y; Kanzawa T; Kyo S; Bekele BN; Zhou X; Nigro J; McDonald JM; Yung WK; Gomez-Manzano C
J Natl Cancer Inst; 2005 Nov; 97(21):1589-600. PubMed ID: 16264179
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effect of brain-specific angiogenesis inhibitor 1 on glioblastoma: an animal experiment].
Xiao XR; Kang XX; Zhao JZ
Zhonghua Yi Xue Za Zhi; 2006 May; 86(19):1342-6. PubMed ID: 16796906
[TBL] [Abstract][Full Text] [Related]
20. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
